Oruka Therapeutics, Inc. (ORKA)
Health Care ยท Pharmaceutical Preparations
Oruka Therapeutics, Inc. (ORKA) is listed on Nasdaq, where its shares have traded since September 3, 2024. SentiSense covers Oruka Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Lawrence Klein is its chief executive officer. The company reports 68 employees, and its corporate website is www.orukatx.com.
About Oruka Therapeutics, Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Latest reported results
Oruka Therapeutics, Inc. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 249 institutions reported holding ORKA, with 74.1 million shares worth $7.1 billion in aggregate. The largest reported holders were FMR, BlackRock and VR Adviser. Of the 5 largest reported holders, 1 opened a new position in ORKA, 2 added shares and 2 held their positions unchanged during the quarter.
More on ORKA
- ORKA sentiment: whether news and social coverage of Oruka Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- ORKA ownership: all 249 reporting institutions, plus insider and congressional trades.
- ORKA financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Oruka Therapeutics, Inc. do?
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications.
What sector is ORKA in?
SentiSense classifies Oruka Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does ORKA stock trade?
Oruka Therapeutics, Inc. (ORKA) is listed on Nasdaq, where its shares have traded since September 3, 2024.
Who is the CEO of Oruka Therapeutics, Inc.?
Lawrence Klein is the chief executive officer of Oruka Therapeutics, Inc..